Literature DB >> 23807347

Efficacy of selective laser trabeculoplasty in phakic and pseudophakic eyes.

Göktuğ Seymenoğlu1, Esin F Baser.   

Abstract

PURPOSE: To compare the efficacy of selective laser trabeculoplasty (SLT) in phakic and pseudophakic eyes in open-angle glaucoma and ocular hypertension.
MATERIALS AND METHODS: Charts of 28 pseudophakic eyes and 60 phakic eyes that underwent 360-degree SLT were retrospectively reviewed. Patients were examined at 1, 3, 6, and 12 months. Treatment success was defined as ≥20% intraocular pressure (IOP) reduction, with no additional medications, laser, or glaucoma surgery. Mean IOP change, mean percentage of IOP reduction, and success rates for phakic and pseudophakic eyes were compared.
RESULTS: Mean percentage of IOP reduction post-SLT at 1-, 3-, 6-, and 12-month visits were 21.4%, 25.8%, 24.8%, and 23.7%, respectively, in the pseudophakic group and 22.8%, 25.0%, 25.7%, and 21.2%, respectively, in the phakic group. Success rates ranged between 60% and 64% in the pseudophakic group and between 58% and 73% in the phakic group. No statistically significant differences in IOP change, percentage of IOP reduction, and success rate were seen between the groups at any of the post-SLT visits (P>0.05).
CONCLUSIONS: Application of 360-degree SLT seems to be an efficient and safe treatment option for the management of phakic and pseudophakic open-angle glaucoma and ocular hypertension.

Entities:  

Mesh:

Year:  2015        PMID: 23807347     DOI: 10.1097/IJG.0b013e31829d9b77

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  2 in total

1.  Selective laser trabeculoplasty in pseudophakic and phakic eyes: a prospective study.

Authors:  Myrjam De Keyser; Maya De Belder; Veva De Groot
Journal:  Int J Ophthalmol       Date:  2017-04-18       Impact factor: 1.779

2.  Clinical results of selective laser trabeculoplasty in silicone oil-induced secondary glaucoma.

Authors:  Miaomiao Zhang; Bin Li; Jianrong Wang; Wei Liu; Yan Sun; Xinyi Wu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-27       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.